HBIO: Summary for Harvard Bioscience, Inc. - Yahoo! Singapore Finance

	Sign In [New User? Sign Up]	Finance Home \|Help

Wednesday, February 10, 2010, 8:53pm SGT - The Singapore stock market is closed.

To create a watchlist or portfolio of shares, Register

FINANCE HOME PAGE

INVESTING

FINANCE NEWS

Harvard Bioscience Inc. (HBIO)

At 5:00AM SGT: 3.42 USD 0.00 (0.00%)

MORE ON HBIO

Quotes

Summary

Charts

News & Info

Company

Analyst Coverage

Ownership

Financials

Harvard Bioscience, Inc. (NGM:HBIO) Delayed quote data

Last Trade:	3.42 USD
Trade Time:	5:00AM SGT
Change:	0.00 (0.00%)
Prev Close:	3.42
Open:	N/A
Bid:	N/A
Ask:	N/A
1y Target Est:	6.00

Day's Range:	N/A - N/A
52wk Range:	2.38 - 4.31
Volume:	0
Avg Vol (3m):	79,938.1
Market Cap:	100.78M
P/E (ttm):	18.69
EPS (ttm):	0.18
Div & Yield:	N/A (N/A%)

1d 5d 3m 6m 1y 2y 5y max

Use Y! Toolbar to track stocks

Add HBIO to Portfolio

Download Data

HEADLINES

•	HBIO President David Green to Present January 19, 2010 at Global Investor Day 2010
	GlobeNewswire (Tue, Jan 12)

•	Better Buy: Harvard Bioscience or Thermo Fisher Scientific?
	at Motley Fool (Wed, Dec 9)

•	HARVARD BIOSCIENCE INC Files SEC form 8-K/A, Financial Statements and Exhibits
	EDGAR Online (Fri, Nov 20)

•	HARVARD BIOSCIENCE INC Financials
	EDGAR Online Financials (Fri, Nov 13)

•	HARVARD BIOSCIENCE INC Files SEC form 10-Q, Quarterly Report
	EDGAR Online (Tue, Nov 10)

•	HARVARD BIOSCIENCE INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Ex
	EDGAR Online (Thu, Nov 5)

•	HBIO Reports Third Quarter 2009 Revenue Growth of 5% Over Third Quarter 2008
	GlobeNewswire (Thu, Nov 5)

•	Harvard Bioscience, Inc. Schedules Third Quarter 2009 Conference Call for November 4, 2009
	GlobeNewswire (Fri, Oct 23)

•	HBIO President David Green to Present At 2009 UBS Global Life Sciences Conference On September 23, 2009
	GlobeNewswire (Thu, Sep 10)

•	HARVARD BIOSCIENCE INC Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Financial Statements a
	EDGAR Online (Thu, Sep 10)

More Headlines for HBIO...

ANALYST

EPS Est (next year) (Dec-09) :	N/A
EPS Est (in 2 years) (Dec-10) :	N/A
Avg Rec (current)*:	3.0
PEG Ratio:	N/A

* (Strong Buy) 1.0 - 5.0 (Strong Sell)

Analyst Opinion - Estimates

BUSINESS SUMMARY

Harvard Bioscience, Inc. develops, manufactures, distributes, and markets apparatus and scientific instruments used in life science research at pharmaceutical and biotechnology companies, universities, and government laboratories worldwide.

Full Company Profile

Add to Portfolio

Email to a Friend

•